LLY

891.61

+0.7%↑

NVO

140.76

+0.14%↑

UNH

480.58

-1.8%↓

JNJ

145.68

-0.23%↓

MRK

127.92

+0.24%↑

LLY

891.61

+0.7%↑

NVO

140.76

+0.14%↑

UNH

480.58

-1.8%↓

JNJ

145.68

-0.23%↓

MRK

127.92

+0.24%↑

LLY

891.61

+0.7%↑

NVO

140.76

+0.14%↑

UNH

480.58

-1.8%↓

JNJ

145.68

-0.23%↓

MRK

127.92

+0.24%↑

LLY

891.61

+0.7%↑

NVO

140.76

+0.14%↑

UNH

480.58

-1.8%↓

JNJ

145.68

-0.23%↓

MRK

127.92

+0.24%↑

LLY

891.61

+0.7%↑

NVO

140.76

+0.14%↑

UNH

480.58

-1.8%↓

JNJ

145.68

-0.23%↓

MRK

127.92

+0.24%↑

Search

Alkermes PLC

Open

Sector Healthcare

24.44 -2.2

Overview

Share price change

24h

Current

Min

24.43

Max

24.75

Key metrics

By Trading Economics

Income

-76M

37M

Sales

-27M

350M

P/E

Sector Avg

18.362

23.904

EPS

0.43

Profit margin

10.51

EBITDA

-31M

61M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+39.94 upside

Dividends

By Dow Jones

Next Earnings

24 lip 2024

Market Stats

By TradingEconomics

Market Cap

236M

4.1B

Previous open

26.64

Previous close

24.44

News Sentiment

By Acuity

50%

50%

124 / 370 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Alkermes PLC Chart

Related News

14 gru 2023, 11:06 UTC

Acquisitions, Mergers, Takeovers

Alkermes Athlone Facility Has About 400 Employees >ALKS

14 gru 2023, 11:06 UTC

Acquisitions, Mergers, Takeovers

Alkermes to Get Cash Payment of $92.5 Million for Facility, Related Assets >ALKS

Peer Comparison

Price change

Alkermes PLC Forecast

Price Target

By TipRanks

39.94% upside

12 Months Forecast

Average 35 USD  39.94%

High 50 USD

Low 23 USD

Based on 12 Wall Street analysts offering 12 month price targets forAlkermes PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

12 ratings

7

Buy

4

Hold

1

Sell

Technical Score

By Trading Central

24.25 / 24.79Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

124 / 370 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.